Strategic Focus Target CNS and eye diseases caused by haploinsufficiency, with a near-term emphasis on Dravet syndrome using the TANGO ASO platform, presenting a specific therapeutic niche for collaboration, partnerships, and potential co-development discussions.

Clinical Progress Zorevunersen is in Phase 3 for Dravet syndrome, signaling late-stage development risk tolerance and potential near-term collaboration opportunities with partners or funding stakeholders seeking late-stage assets or proof-of-concept expansion.

Financial Readiness Reported revenue in the lower/mid single digits with substantial funding runway; explore value-based partnerships, milestone-driven licensing, or co-development deals to accelerate clinical expansion and diversify funding sources.

Strategic Partnerships Recent collaboration announcements with Biogen for data presentation and leadership changes (new CSO) indicate openness to strategic alliances, co-development, and external scientific input to advance the TANGO platform.

Market Positioning Pipeline focus on restoring protein expression via ASOs addresses haploinsufficiency across CNS and ocular indications, presenting opportunities to engage adjacent indications, biomarkers, and patient access programs to broaden addressable market.